Artelo Biosciences, Inc. Announces Board Appointments
Effective as of May 2, 2017, the board of Artelo Biosciences, Inc. increased its size from two members to four members and appointed Connie Matsui as a member of the board and the chair of the board and Steven Kelly as a member of the board to serve in such capacity for a period of four years, subject to their earlier resignation or removal. Ms. Matsui currently serves as the chair of the board at Halozyme and has been active on a number of not-for-profit boards. Since 2012, Mr. Kelly has been the principal of Kelly BioConsulting, LLC, and serves as an independent consultant providing strategic direction and guidance to a variety of life sciences companies. Most recently, Mr. Kelly was the founding CEO of Pinteon Therapeutics. Prior to this he held a number of leadership positions in the biotechnology industry including: CEO, Theracrine; CCO, BioVex; CEO, Innovive Pharmaceuticals; as well as various commercial and manufacturing roles at Sanofi, IDEC Pharmaceuticals and Amgen.